News Cidara Therapeutics, Inc.

Equities

CDTX

US1717572069

Real-time Estimate Cboe BZX Other stock markets 03:23:19 2024-04-25 pm EDT			5-day change	1st Jan Change
12.65 ^USD	+2.93%		-11.84%	-19.83%

02:28pm	Top Premarket Gainers	MT
12:07pm	North American Morning Briefing : More Tech -2-	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX	11:26am	BU
CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO MUNDIPHARMA TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF CLOUDBREAK DFC PIPELINE	10:21am	AQ
Top Premarket Gainers	08:28am	MT
North American Morning Briefing : More Tech -2-	06:07am	DJ
North American Morning Briefing : More Tech Earnings in Focus With GDP Data Adding to the Uncertainty	06:06am	DJ
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset	Apr. 24	DJ
Transcript : Cidara Therapeutics, Inc. - Special Call	Apr. 24
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million	Apr. 24	AQ
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline	Apr. 24	AQ
Mundipharma International Limited acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc..	Apr. 23	CI
Cidara Therapeutics, Inc. announced that it has received $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors	Apr. 23	CI
Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket	Apr. 23	MT
Cidara Therapeutics, Inc. announced that it expects to receive $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors	Apr. 22	CI
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q4 Revenue $17.6M	Apr. 22	MT
Cidara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 22	CI
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	Apr. 22	AQ
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice	Apr. 22	AQ
Cidara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 22	CI
Cidara Therapeutics to Effect 1-for-20 Reverse Stock Split	Apr. 22	MT
Cidara Therapeutics Announces Reverse Stock Split	Apr. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cidara Therapeutics, Inc.

Equities

CDTX

US1717572069

Summary

Filters